https://novartis-be-lux-newsroom-medical-press.prezly.com/nl daily 0.9 https://novartis-be-lux-newsroom-medical-press.prezly.com/en daily 0.9 https://novartis-be-lux-newsroom-medical-press.prezly.com/ daily 0.9 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-scemblixr-obtient-lapprobation-de-la-commission-europeenne-pour-le-traitement-des-adultes-atteints-de-leucemie-myeloide-chroniquea-lmc-y-compris-nouvellement-diagnostiques weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-scemblixr-krijgt-goedkeuring-van-de-europese-commissie-voor-de-behandeling-van-volwassenen-chronische-myeloide-leukemiea-cml-inclusief-nieuw-gediagnosticeerde-patienten weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/fabhaltar-iptacopan-terugbetaald-in-belgie-nieuwe-hoop-voor-volwassen-c3g-patienten-door-aanpak-van-de-onderliggende-oorzaak weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/fabhaltar-iptacopan-rembourse-en-belgique--un-nouvel-espoir-pour-les-adultes-atteints-de-c3g-grace-a-un-traitement-qui-agit-sur-la-cause-de-la-maladie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/lextension-du-remboursement-de-kisqalir-renforce-la-protection-contre-les-rechutes-chez-les-patientes-atteintes-dun-cancer-du-sein-au-stade-precoce weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/uitbreiding-terugbetaling-kisqalir-biedt-vroege-borstkankerpatienten-betere-bescherming-tegen-herval weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-oral-fabhaltar-iptacopan-recoit-lapprobation-de-la-commission-europeenne-pour-le-traitement-des-adultes-atteints-de-glomerulopathie-c3-c3g weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-orale-fabhaltar-iptacopan-krijgt-goedkeuring-van-de-europese-commissie-voor-de-behandeling-van-volwassenen-met-c3-glomerulopathie-c3g weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/kisqali-approuve-par-la-commission-europeenne-pour-le-traitement-du-cancer-du-sein-rhher2-au-stade-precoce-a-haut-risque-de-rechute weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/kisqali-goedgekeurd-door-europese-commissie-voor-hrher2--borstkanker-in-een-vroeg-stadium-met-hoog-risico-op-herval weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/fabhaltar-la-premiere-monotherapie-orale-pour-le-traitement-de-lhpn-remboursee-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/fabhaltar-eerste-orale-monotherapie-voor-de-behandeling-van-pnh-terugbetaald-in-belgie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-recoit-lapprobation-de-la-commission-europeenne-pour-fabhaltar-iptacopan-la-premiere-monotherapie-administree-par-voie-orale-pour-les-adultes-souffrant-dhemoglobinurie-paroxystique-nocturne weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-krijgt-goedkeuring-van-de-europese-commissie-voor-fabhaltar-iptacopan-de-eerste-orale-monotherapie-voor-volwassenen-met-paroxismale-nachtelijke-hemoglobinurie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/le-premier-traitement-approuve-en-europe-pour-les-enfants-souffrant-dinsuffisance-cardiaque-chronique-symptomatique-avec-dysfonction-systolique-ventriculaire-gauche-rembourse-a-partir-du-1er-juin-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/eerste-in-europa-goedgekeurde-therapie-voor-kinderen-met-symptomatisch-chronisch-hartfalen-met-linkerventrikeldisfunctie-vanaf-1-juni-in-belgie-terugbetaald weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/la-premiere-therapie-par-radioligands-approuvee-par-lema-pour-le-traitement-du-cancer-de-la-prostate-remboursee-pour-les-patients-atteints-de-mcrpc-a-partir-du-1er-avril-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/eerste-ema-goedgekeurde-radioligandtherapie-voor-behandeling-prostaatkanker-vanaf-1-april-in-belgie-terugbetaald-voor-mcrpc-patienten weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/le-remboursement-de-cosentyxr-offre-aux-patients-atteints-dhs-la-perspective-dune-meilleure-qualite-de-vie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/terugbetaling-cosentyxr-biedt-hs-patienten-perspectief-op-betere-levenskwaliteit weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/nieuwe-cdk46i-data-op-asco-2022-bekrachtigen-kisqalir weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/de-nouvelles-donnees-sur-linhibiteur-des-cdk46-kisqalir-presentees-a-lasco-2022 weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/innovatieve-langwerkende-cholesterolverlager-leqvior-vanaf-1-mei-terugbetaald-in-belgie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/leqvio-lhypocholesterolemiant-innovant-a-longue-duree-daction-rembourse-a-partir-du-1er-mai-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/odysightr-une-solution-digitale-pour-accompagner-a-distance-les-patients-atteints-de-maladies-oculaires-chroniques-est-a-partir-de-maintenant-disponible-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/patienten-met-chronische-oogziekten-virtueel-thuis-opvolgen-met-odysightr weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/le-stylo-cosentyxr-300-mg-rend-ladministration-plus-facile-pour-les-patients-atteints-de-psoriasis-tout-en-garantissant-lefficacite-et-la-securite weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/met-de-cosentyxr-300-mg-pen-kunnen-psoriasispatienten-hun-behandeling-gemakkelijker-toedienen-terwijl-de-werkzaamheid-en-veiligheid-gegarandeerd-zijn weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/bonne-nouvelle-pour-les-patients-atteints-de-sma-en-belgique weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/goed-nieuws-voor-sma-patienten-in-belgie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/mayzentr-la-premiere-et-seule-option-therapeutique-par-voie-orale-pour-ralentir-la-progression-de-la-sclerose-en-plaques-secondaire-progressive weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/ziekteprogressie-vertragen-in-actieve-secundair-progressieve-multiple-sclerose-met-eerste-en-enige-orale-behandeloptie-mayzentr weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/plus-de-temps-pour-les-personnes-atteintes-dun-cancer-du-sein-avance--de-nouvelles-donnees-relatives-a-kisqalir-de-la-firme-novartis-montrent-une-survie-globale-mediane-de-plus-de-cinq-ans-soit-la-plus-longue-jamais-enregistree-dans-le-canc weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/meer-tijd-voor-mensen-met-gevorderde-borstkanker-nieuwe-kisqalir-data-tonen-meer-dan-vijf-jaar-totale-overleving-bij-hrher2-gemetastaseerde-borstkanker weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/kesimptar-le-premier-et-lunique-traitement-auto-administre-ciblant-les-lymphocytes-b-est-rembourse-pour-les-patients-adultes-atteints-de-sclerose-en-plaques-recurrente weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/terugbetaling-voor-kesimptar-de-eerste-en-enige-gerichte-b-celtherapie-voor-zelftoediening-voor-volwassen-patienten-met-relapsing-multiple-sclerose weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-annonce-la-plus-longue-survie-globale-mediane-chez-les-patientes-menopausees-atteintes-dun-cancer-du-sein-metastatique-hrher2 weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/novartis-kondigt-de-langste-mediane-globale-overleving-aan-bij-postmenopauzale-vrouwen-met-hrher2-gemetastaseerde-borstkanker weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/enerzairr-breezhalerr--le-controle-de-lasthme-devient-un-objectif-realisable-pour-les-patients-et-les-medecins weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/met-enerzairr-breezhalerr-wordt-astmacontrole-een-bereikbaar-doel-voor-patienten-en-artsen weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/aimovigr-le-tres-attendu-traitement-innovant-pour-la-prevention-de-la-migraine-est-rembourse-a-partir-du-1-juin weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/langverwachte-innovatieve-behandeling-aimovigr-vanaf-1-juni-terugbetaald-voor-migraine-preventie weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/pour-la-premiere-fois-une-therapie-genique-dans-le-traitement-dune-maladie-oculaire-rare-est-remboursee weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/eerste-gentherapie-voor-het-behandelen-van-ernstige-zeldzame-oogziekte-terugbetaald weekly 0.7 https://novartis-be-lux-newsroom-medical-press.prezly.com/category/covid-19 weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/nl/category/covid-19 weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/category/novartis-belgique weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/nl/category/novartis-belgie weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/category/novartis-puurs weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/nl/category/novartis-puurs weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/category/traitements-innovants weekly 0.8 https://novartis-be-lux-newsroom-medical-press.prezly.com/nl/category/innovatieve-behandelingen weekly 0.8